Chromium picolinate

PreclinicalSmall molecule

PPennington Biomedical Research Center

Chromium picolinate is one of 49 small molecule programs targeting Metabolic Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

Acanthosis NigricansActive, not recruiting

Metabolic SyndromePreclinical

Active, not recruiting

Acanthosis NigricansPreclinical

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

6 2

Actos

Takeda

Approved

5 3

Cosentyx

Novartis

Approved

3 4

Avandia

Jazz Pharmaceuticals

Approved

2 5

Ozempic

Novo Nordisk

Approved

1 6

Bayer Aspirin

Bayer

Approved

1 7

Uloric

Takeda

Approved

1 8

Victoza

Novo Nordisk

Approved

1 9

Geodon

Pfizer

Approved

1 10

Niacor

AbbVie

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes

Terminated·—·Phase 1·NCT00332085·40 enrolled

Acanthosis Nigricans1 trial

Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin Resistance

Completed·UUruk University·N/A·NCT07371169·90 enrolled

Metabolic Syndrome1 trial

Chromium Picolinate for the Treatment of Metabolic Syndrome

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·N/A·NCT00128154·60 enrolled

Unspecified2 trials

Chromium and Insulin Action

Completed·PPennington Biomedical Research Center·Phase 4·NCT00283777·30 enrolled

Effects of Chromium Picolinate on Food Intake

Completed·PPennington Biomedical Research Center·N/A·NCT00477854·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Chromium picolinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chromium picolinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chromium picolinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pennington Biomedical Research Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPennington Biomedical Research Center

Chromium picolinate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes1 trial

Acanthosis Nigricans1 trial

Metabolic Syndrome1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News